Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04355767 · ClinicalTrials.gov registry record · Phase 3
Convalescent Plasma in Outpatients With COVID-19
A Phase 3 study of Covid19, sponsored by Stanford University.
- Completed
- Registry status
- Phase 3
- Development phase
- 511
- Enrollment target
- 20
- Study locations
NCT04355767 is a Phase 3 study of Covid19 that has completed, run by Stanford University. The registered enrollment target is 511 participants, below the 2,697-participant average among 94 other Covid19 trials with a reported enrollment target (81% lower). The trial reports 20 study locations across 10 states.
The verdict
NCT04355767, a Phase 3 study of Covid19, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 511 participants
- Enrollment target
- 20
- Study locations
Study Summary
The overarching goal of this project is to confirm or refute the role of passive immunization as a safe and efficacious therapy in preventing the progression from mild to severe/critical COVID-19 illness and to understand the immunologic kinetics of anti-SARS-CoV-2 antibodies after passive immunization.The primary objective is to determine the efficacy and safety of a single dose of convalescent plasma (CP) for preventing the progression from mild to severe COVID-19 illness. The secondary objective is to characterize the immunologic response to CP administration. This study will enroll adults presenting to the emergency department (ED) with mild, symptomatic, laboratory-confirmed COVID-19 illness, who are at high risk for progression to severe/critical illness, but who are clinically stable for outpatient management at randomization.
Conditions Studied
Interventions
- BIOLOGICAL Saline
- BIOLOGICAL Convalescent Plasma
Study Locations (20)
California
- UCSD Health La Jolla - La Jolla
- Loma Linda University Medical Center - Loma Linda
- Ronald Reagan UCLA Medical Center - Los Angeles
- Cedars-Sinai Medical Center - Los Angeles
- UC Davis Medical Center - Sacramento
- Stanford University - Stanford
- Harbor-UCLA Medical Center - Torrance
Illinois
- Rush University Medical Center - Chicago
- University of Illinois Hospital - Chicago
- University of Chicago Medical Center - Chicago
Arizona
- Chandler Regional Medical Center - Chandler
- Valleywise Health Medical Center - Phoenix
Florida
- UF Health Shands Hospital - Gainesville
- Jackson Memorial Hospital - Miami
Colorado
- University of Colorado Hospital - Aurora
Georgia
- Grady Memorial Hospital - Atlanta
Iowa
- University of Iowa Hospitals & Clinics - Iowa City
Kentucky
- University of Louisville Hospital - Louisville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 511 participants |
| Start Date | 2020-08-11 |
| Est. Completion | 2021-03-29 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04355767
The ClinicalTrials.gov registry entry for NCT04355767 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 511 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,697-participant average among 94 other Covid19 trials with a reported enrollment target (81% lower). The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Covid19 appearing as the primary indexed condition, and to 2 interventions - of which Saline is the first listed.
NCT04355767 reports 20 study locations spanning 10 distinct geographic areas - top geographies include California, Illinois, Arizona.
Frequently Asked Questions
What is clinical trial NCT04355767 about?
NCT04355767 is a clinical study titled "Convalescent Plasma in Outpatients With COVID-19". The overarching goal of this project is to confirm or refute the role of passive immunization as a safe and efficacious therapy in preventing the progression from mild to severe/critical COVID-19 illness and to understand the immunologic kinetics of anti-SARS-CoV-2 antibodies after passive immunizat...
What is the current status of trial NCT04355767?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 511 participants. The study started on 2020-08-11. Estimated completion is 2021-03-29.
What conditions does trial NCT04355767 study?
This clinical trial studies the following conditions: Covid19.
What interventions are being tested in trial NCT04355767?
The interventions under investigation include: Saline (BIOLOGICAL), Convalescent Plasma (BIOLOGICAL).
Who is sponsoring clinical trial NCT04355767?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04355767 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Covid19
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Outpatient Treatment With Anti-Coronavirus Immunoglobulin
RECRUITING · Phase 3
-
Convalescent Plasma Collection and Treatment in Pediatrics and Adults
RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults ≥ 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2
COMPLETED · Phase 3
-
Aggrenox To Treat Acute Covid-19
COMPLETED · Phase 3
-
COVID-OUT: Early Outpatient Treatment for SARS-CoV-2 Infection (COVID-19)
COMPLETED · Phase 3
-
Contrast Enhanced Ultrasound in COVID-19
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.